{"url_path":"/sec/dcoy/8-k/2026-06-29/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-29","source_url":"https://www.sec.gov/Archives/edgar/data/1615219/0001193125-26-286737-index.html","accession_number":"0001193125-26-286737","cik":"0001615219","ticker":"DCOY","issuer_name":"Decoy Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1615219/0001193125-26-286737-index.html","primary_entity_key":"0001615219","primary_entity_name":"Decoy Therapeutics Inc."},"word_count":300,"has_tables":true,"body_markdown":"Item 7.01. Regulation FD Disclosure.\n\nOn June 26, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.\n\nThe information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing.\n\nForward-Looking Statements\n\nThis Current Report on Form 8-K contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the expected closing of the Private Placement, the anticipated gross proceeds therefrom and the potential additional proceeds from the exercise of the Milestone Warrants, the anticipated use of proceeds, the timing of the filing and effectiveness of the resale registration statement, the Company’s ability to obtain Stockholder Approval, and the Company’s development plans and milestones. These statements are based on current beliefs and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including the risk that the closing conditions to the Private Placement are not satisfied, that the Company does not obtain Stockholder Approval, that the applicable milestones are not achieved, and the other risks and uncertainties described in the Company’s filings with the SEC, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company undertakes no obligation to update any forward-looking statements except as required by law."}